Leitlinienreport zur S3-Leitlinie Magenkarzinom – „Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs“

1. Informationen zum Leitlinienreport

1.1. Autoren des Leitlinienreports

Markus Moehler, Thomas Langer, Tanja Bender, Julia Kofent, Friederike Greiwe, Heinrike Jost, Georgia Koukli, Annika Orthey, Carolin Rolfes, Catharina Wald, Simone Wesselmann, Markus Follmann, Susanne Unverzagt

Tab. 1 Mitarbeit an der Leitlinie.

Art der Tätigkeit	Zeitraum	Name
Statistische Doktoranden	2014–2016	Hannah Andrae, Yousif Faddah, Christian Hagemann, Daniel Krutsch
Statistische Doktoranden	2016–2018	Friederike Greiwe, Heinrike Jost, Georgia Koukli, Annika Orthey, Caroline Rolfes, Catharina Wald
Freie Mitarbeit	2018	Dr. rer. nat. Julia Kofent

1.2. Herausgeber

Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Deutschen Krebsgesellschaft e. V. (DKG) und Deutsche Krebshilfe (DKH).

1.3. Federführende Fachgesellschaft(en) der Leitlinie

Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten e. V.

1.4. Finanzierung der Leitlinie

Die Erstellung und Aktualisierung dieser Leitlinie wurde von der Deutschen Krebshilfe im Rahmen des Leitlinienprogramms Onkologie gefördert.

1.5. Kontakt

Office Leitlinienprogramm Onkologie c/o Deutsche Krebsgesellschaft e. V.
Kuno-Fischer-Straße 8
14057 Berlin
[e-mail]
www.leitlinienprogramm-onkologie.de

1.6. Zitierweise des Leitlinienreports

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Magenkarzinom, Leitlinienreport Version 2.0, 2019, AWMF Registernummer: 032/009OL, https://www.leitlinienprogramm-onkologie.de/

1.7. Weitere Dokumente zur Leitlinie

Die Leitlinie liegt als Lang- und Kurzversion vor. Außerdem gibt es eine Patientenleitlinie (Laienversion der Leitlinie). Alle Dokumente zur Leitlinie sind über die folgenden Seiten zugänglich:

• AWMF (http://www.awmf.org/leitlinilen/aktuelle-leitlinien.html)

• Leitlinienprogramm Onkologie (https://www.leitlinienprogramm-onkologie.de/leitlinien/magenkarzinom/)

• Guidelines International Network (www.g-i-n.net)

• Beteiligte Fachgesellschaften (z. B. https://www.dgvs.de/wissen-kompakt/leitlinien/leitlinien-der-dgvs/)

1.8. Allgemeine Informationen zur Leitlinie

In der Langversion der Leitlinie sind die Adressaten und diejenigen Ziele aufgeführt, die mit der Erstellung und Implementierung der Leitlinie verfolgt werden. Darüber hinaus enthält die Langversion Angaben zur Gültigkeit, dem geplanten Aktualisierungsverfahren und den Personen und Institutionen, die an der Erstellung der Leitlinien beteiligt waren.

1.9. Abkürzungsverzeichnis

Tab. 2 Abkürzungsverzeichnis

Abkürzung	Erläuterung
18F-FDG PET/CT	18 Fludeoxyglucose – PET/CT
18-F-FLT-PET	18 F – Fluorothymidin Positron Emissions Tomografie
5-FU	5-Fluorouracil
AE	Adverse Event; unerwünschtes Ereignis
AEG	Adenokarzinom des ösophagogastralen Übergangs
AFI-NBI	Autofluorescence imaging – narrowband imaging
AJCC	American Joint Committee on Cancer; Amerikanisches Krebskomitee
AL	Chromosomenendoskopie mit Indigocarmin Farbstoff plus Essigsäure
AMFR	Autokriner Motilitätsfaktor-Rezeptor
ASA	Risikoklassifikation der American Society of Anaesthesiologists
ASCO	American Society of Clinical Oncology; Amerikanische Krebsgesellschaft
ASPC	Accordion Severity Classification of Postoperative Complications
AUC	Area under the curve
AWMF	Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V.
ÄZQ	Ärztliches Zentrum für Qualität in der Medizin
BMI	Body Mass Index
BSC	Best supportive care
CA19–9	Carboanhydrate Antigen 19–9
CAIX	Carboanhydrase IX
CEA	Carcinoembryonales Antigen
CEBM	Oxford Centre for Evidence-based Medicine
ceMDCT	Contrast-enhanced multidetector-row computer tomography
CENTRAL	Cochrane Central Register of Controlled Trials
CG	Conventional group; Konventionelle Gruppe
CHPP	(Intraoperative) chemohyperthermic peritoneal perfusion
CINAHL	Cumulative Index to Nursing and Allied Health Literature
CLE	Konfokale Laser Endomikroskopie
CNS	Central Nervous System; zentrales Nervensystem
CR	Complete remission; Komplette Remission
CR+PR	Response; Ansprechen
CRP	C-reaktives Protein
CRS	Cytoreductive surgery; zytoreduktive Chirurgie
CT	Computertomografie
CTh	Chemotherapie
CTLA-4	Zytotoxische T-Lymphozyten assoziiertes Molekül 4
CTX	Chemotherapie
Cvc	Computed virtual chromoendoscopy
Cyt-	Negative Zytologie
Cyt+	Positive Zytologie
DCF	Chemotherapy Regime containing Docetaxel, Cisplatin and 5-FU
DFS	Disease free survival; Krankheitsfreies Überleben
DKG	Deutsche Krebsgesellschaft e. V.
DKH	Deutsche Krebshilfe e. V.
DOR	Diagnostische Odds Ratio
DSS	Krankheitsspezifisches Überleben
EBV	Ebstein-Barr-Virus
ECF	Epirubicin, Cisplatin, Fluorouracil
ECG	Early gastric cancer
ECOG	Leistungsstatus/Eastern Co-operative Oncology Group
ECX	Epirubicin, Cisplatin, Capecitabine
EGC	Early gastric cancer
EGFR	Epidermal Growth Factor Receptor
ELISA	Enzyme-linked Immunosorbent Assay
EMBASE	Excerpta Medica dataBASE
EMR	Endoskopische Mukosaresektion
EOF	Epirubicin, 5-Fluorouracil, Oxaliplatin
ErbB2	Human epidermal growth factor receptor 2
ERCC1	Excision repair cross complementation-Gruppe 1
ESD	Endoskopische Submukosa-Dissektion
ESMO	European Society for Medical Oncology
EUS	Endoskopischer Ultraschall
EUS	Endoskopischer Ultraschall (Syn. Endosonografie)
F	Female
FEM	Fixed Effektmodel
FEV1	Forcierte Einsekundenkapazität
FGFR2	Fibroblasten Wachstumsfaktorrezeptor 2
FGL	Focal gastric lesion
FLO	5-FU, Leucovorin, Oxaliplatin
FLOT	5-FU, Leucovorin, Oxaliplatin, Docetaxel
FN	False negative
FOLFIRI	Folinsäure, 5-FU, Irinotecan
FP	False positive
G/GEJ	Magenadenokarzinom und Adenokarzinom des Gastroösophagealen Übergangs
GC	Gastric Cancer (Magenkarzinom)
GEJ	Gastroesophageal Junction
GEKID	Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.
GENs	Gastroösophageale Neoplasien
G-I-N	Guidelines International Network
Gy	Gray
H.p.	Helicobacter pylori
HD-WLE	High-definition white light endoscopy
HER2	Humaner epidermaler Wachstumsfaktor-Rezeptor 2
HIPEC	Hypertherme intraperitoneale Chemotherapie
HR	Hazard Ratio
HTA	Health Technology Report
I2	Heterogenitätsmaß
IGKC	Immunglobulin kappa C
ich	Immunhistochemie
IM	Intestinale Metaplasie
int.	international
IPC	Intraperitoneal chemotherapy
IPCC	Intraperitoneale freie Krebszellen
IPHC	Intraperitoneal hyperthermic chemoperfusion
IQR	Interquartile range
IQWiG	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
ITT	Intention-to-treat
J	Jahre
JG	Jumbo-Zangen
k. A.	Keine Angabe
KI	Konfidenzintervall
LADG	Laparoskopisch-assistierte distale Gastrektomie
LAG	Laparoskopisch-assistierte Gastrektomie
LG	Laparoskopische distale Gastrektomie
LN	Lymph node
LR	Likelihood ratio
Lv	Leucovorin
M	männlich
MA	Meta-Analyse
MAPF–	Negativer
MAPF +	Positiver
MCT4	Monocarboxylattransporter 4 Protein
MD	Mittlere Differenz
mDCF	Modified Chemotherapy Regime containing Docetaxel, Cisplatin and 5-FU
MDCT/MD-CT	Multi-Detektor-Computertomografie
MEDLINE	MEDical Literature Analysis and Retrieval System OnLINE
ME-NBI	Magnifying endoscopy-narrow-band imaging
MET/Met	tyrosine-protein kinase Met
MMR	Mismath Repair
MRI	Magnetic resonance imaging
MRT	Magnetresonanztomografie
MSI	Mikrosatelliteninstabilität
N	Number of patients; Zahl der Patienten
NBI	Narrow band imaging
NGC	National Guideline Clearinghouse
NIH	National Institutes of Health
NM	mikroskopisch negativer (tumorfreier) Resektionsrand
NNT	Number needed to treat
NPV	Negativ prädiktiver Wert
nRT	chirurgische Resektion ohne Radiotherapie
NYHA Stadium	Stadieneinteilung der Herzinsuffizienz der New York Heart Association
OCEBM	Oxford Centre for Evidence-based Medicine
ODG	offene distale Gastrektomie
OG	offene Gastrektomie
OL	Leitlinienprogramm Onkologie
OR	Odds Ratio
ORR	objektive Ansprechrate
OS	Gesamtüberleben
P	p-value (probability)
P	Result of Cochranʼs Q test
PC	Peritonealkarzinose
PCR	Polymerasekettenreaktion
pCR	histopathologisch komplette Remission
PD	Progressive Krankheit
PD	Peritonealerkrankung
PD-L1	Programm-Zelltod 1 Ligand 1
PET	Positonen-Emissions-Tomografie
PET-CT	Positonen-Emissions-Tomografie-Computertomografie
PFS	Progressionsfreies Überleben
PIPAC	Pressurized Intraperitoneal Aerosol Chemotherapy
PL	Peritoneallavage
PM	mikroskopisch positiver Resektionsrand
pPR	histopathologisch partielle Regression
PPV	Positv prädiktiver Wert
PR	Partielle Remission
PRF	Rekurrentes freies Überleben
PRSC	prognostischer Score
PS	Performance status
QLQ-C30	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 items version 3, Karnofsky
QoL	Quality of life
QUADAS	Quality Assessment of Diagnostic Accuracy Studies
R0	mikroskopisch negativer (tumorfreier) Resektionsrand
R1	mikroskopisch positiver Resektionsrand
RCT	Randomized controlled trails; randomisierte kontrollierte Studie
RCT	Radiochemotherapie
RD	Risikodifferenz
RECIST	Response Evaluation Criteria In Solid Tumors
REM	Random Effect Model
RFS	Regressionsfreies Überleben
ROC	Receiver Operating Characteristic
RR	Relatives Risiko
RT	chirurgische Resektion mit adjuvanter Radiotherapie
RTK	Rezeptor Tyrosinkinase
SC	Supportive care
SD	Stabile Erkrankung
SD+PD	Nonresponse
SE/Se	Sensitivität
SEER	Surveillance, Epidemiology, and End Result registry database
SL	Staging Laparoskopie
SMD	standardisierte mittlere Differenz
SNP	Single-nucleotide polymorphisms
Spe	Spezifität
SR	Systematischer Review
SUV(max)	Maximaler Standardisierter Uptake-Wert
SUV(peak)	Peak standardized uptake value
TLR(max)	SUV(max) of tumour to SUV(mean) of normal liver ratio
TLR(peak)	SUV(peak) of tumour to liver ratio
TMA	Gewebs-Mikroarrays
TN	True negative
TNF-α	Tumornekrosefaktor α
TNM	Classification system; Klassifikationssystem
TP	True positive, wahr positiv
TRG	Tumorregressionsgrad
TTF	Time to Failure
TTR	Time to recurrence; Zeit bis Rekurrenz
VAP-1	Vaskuläres Adhäsionsprotein-1
UICC	Union internationale contre le cancer
VEGF	Vasculärer Endothelialer Wachstumsfaktor
vs.	versus
W	weiblich
WHO	Weltgesundheitsorganisation
WHO ICTRP	World Health Organization International Clinical Trials Registry Platform
WLE	Weißlicht-Endomikroskopie
WLG	White light gastroscopy; Weißlicht-Gastroskopie
WLI	White light imaging; Weißlichtbilder
x2	Chi square test
z. B.	zum Beispiel

• Literatur

• 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.1. AWMF-Registernummer: 032/051OL. 2014 http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html
• 2 Arends J, Bertz H, Bischoff SC. DGEM Steering Committee. et al. S3-Leitline der Deutschen Gesellschaft für Ernährungsmedizin e.V. (DGEM) in Kooperation mit der Deutschen Gesellschaft für Hämatologie und Onkologie e.V. (DGHO), der Arbeitsgemeinschaft „Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin“ der Deutschen Krebsgesellschaft (ASORS) und der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE). Klinische Ernährung in der Onkologie. Aktuelle Ernaehrungsmedizin 2015; 40: e1-e74
• 3 Porschen R. et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL). Zeitschrift für Gastroenterologie 2015; 53 (11) 1288-1347
• 4 Ajani JA. et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14: 1286-1312
• 5 Smyth EC. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 05) v38-v49
• 6 (AB), A.H.S.E. Gastric cancer, clinical practice guideline GI-008 [Internet]. Available from: http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-gi008-gastric.pdf , Accessed 2017 Feb 10
• 7 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung Langversion 1.1. AWMF-Registernummer: 128/001OL, Mai 2015. http://leitlinienprogramm-onkologie.de/Palliativmedizin.80.0.htm (Zugriff am 28.02.2017)
• 8 https://www.cebm.net/2016/05/ocebm-levels-of-evidence/
• 9 Langer G. et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Z Evid Fortbild Qual Gesundhwes 2012; 106: 357-368
• 10 Kommission, A.d.W.M.F.-S. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Ständige Kommission. 1.. Auflage 2012
• 11 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Ständige Kommission, L. AWMF-Regelwerk „Leitlinien“. 1.. Auflage 2012. [cited 09.12.2013; Available from: http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html
• 12 Alexander PE. et al. World Health Organization strong recommendations based on low- quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. J Clin Epidemiol 2016; 72: 98-106
• 13 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG), D.K.D., Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie. Version 2.0. 2017. 2017 Berlin:
• 14 Plummer M. et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015; 136: 487-490
• 15 Cavaleiro-Pinto M. et al. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 2011; 22: 375-387
• 16 Ford AC. et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014; 348: g3174
• 17 Yaghoobi M. et al. What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis. World J Gastroenterol 2017; 23: 2435-2442
• 18 Corso G. et al.A meta-analysis Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer 2012; 12: 8
• 19 Terasawa T. et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One 2014; 9: e109783
• 20 Huang YK. et al. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0142080
• 21 Tersmette AC. et al. Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res 1990; 50: 6486-6489
• 22 Tran-Duy A. et al. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1706-1719 e5
• 23 Jeon HK. et al. A randomized trial to determine the diagnostic accuracy of conventional vs. jumbo forceps biopsy of gastric epithelial neoplasias before endoscopic submucosal dissection; open-label study. Gastric Cancer 2014; 17: 661-668
• 24 Li Z. et al. Confocal laser endomicroscopy for in vivo detection of gastric intestinal metaplasia: a randomized controlled trial. Endoscopy 2014; 46: 282-290
• 25 Park SR. et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer 2016; 53: 42-50
• 26 Tongtawee T. et al. Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using „Site Specific Biopsy“: a Randomized Control Clinical Trial. Asian Pac J Cancer Prev 2015; 16: 8487-8490
• 27 Li P. et al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis. Ann Nucl Med 2016; 30: 179-187
• 28 Bilici A. et al. The role of (1)(8)F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients’ treatment decision making?. Eur J Nucl Med Mol Imaging 2011; 38: 64-73
• 29 Graziosi L. et al. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour. Ann Ital Chir 2011; 82: 125-129
• 30 Jadvar H. et al. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003; 58: 215-221
• 31 Kim DW, Park SA, Kim CG. Detecting the recurrence of gastric cancer after curative resection: comparison of FDG PET/CT and contrast-enhanced abdominal CT. J Korean Med Sci 2011; 26: 875-880
• 32 Lee DY. et al. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients. Ann Nucl Med 2014; 28: 789-795
• 33 Lee JE. et al. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy. Yonsei Med J 2011; 52: 81-88
• 34 Ma LYG, Fu Z, Han AQ. et al. Value of F-FDG PET/CT in the evaluation of gastric carcinoma. Chin J Nucl Med 2009; 50: 167-170
• 35 Nakamoto Y. et al. Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study. Jpn J Clin Oncol 2009; 39: 297-302
• 36 De Potter T. et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29: 525-529
• 37 Park MJ. et al. Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging 2009; 34: 441-447
• 38 Sharma P. et al. 18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population. Nucl Med Commun 2012; 33: 960-966
• 39 Sim SH. et al. The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer 2009; 9: 73
• 40 Sun L. et al. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results. World J Gastroenterol 2008; 14: 4627-4632
• 41 Yun M. et al. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. J Nucl Med 2005; 46: 953-957
• 42 Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis. Surg Oncol 2013; 22: 162-166
• 43 Ahn DH. et al. Association of the miR-146aC > G, miR-149T > C, miR-196a2T > C, and miR- 499A>G polymorphisms with gastric cancer risk and survival in the Korean population. Mol Carcinog 2013; 52 (Suppl. 01) E39-E51
• 44 Lee JW. et al. Role of (1)(8)F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. Eur J Nucl Med Mol Imaging 2012; 39: 1425-1434
• 45 Smyth E. et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer 2012; 118: 5481-5488
• 46 Wang C. et al. The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. Clin Cancer Res 2016; 22: 1603-1610
• 47 Park JC. et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging 2012; 39: 1107-1116
• 48 Na SJ. et al. Prognostic value of metabolic parameters on preoperative 18F- fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III gastric cancer. Oncotarget 2016; 7: 63968-63980
• 49 Lehmann K. et al. 18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma. Eur J Surg Oncol 2017; 43: 196-202
• 50 Ramos RF. et al. Staging laparoscopy in gastric cancer to detect peritoneal metastases: A systematic review and meta-analysis. Eur J Surg Oncol 2016; 42: 1315-1321
• 51 Asencio F. et al. Video-laparoscopic staging of gastric cancer. A prospective multicenter comparison with noninvasive techniques. Surg Endosc 1997; 11: 1153-1158
• 52 Tsuchida K. et al. Indications for staging laparoscopy in clinical T4M0 gastric cancer. World J Surg 2011; 35: 2703-2709
• 53 Lavonius MI. et al. Staging of gastric cancer: a study with spiral computed tomography, ultrasonography, laparoscopy, and laparoscopic ultrasonography. Surg Laparosc Endosc Percutan Tech 2002; 12: 77-81
• 54 Muntean V. et al. Staging laparoscopy in gastric cancer. Accuracy and impact on therapy. J Gastrointestin Liver Dis 2009; 18: 189-195
• 55 Stell DA. et al. Prospective comparison of laparoscopy, ultrasonography and computed tomography in the staging of gastric cancer. Br J Surg 1996; 83: 1260-1262
• 56 Cardona K. et al. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy. Ann Surg Oncol 2013; 20: 548-554
• 57 Convie L. et al. The current role of staging laparoscopy in oesophagogastric cancer. Ann R Coll Surg Engl 2015; 97: 146-150
• 58 Bonenkamp JJ. et al. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996; 83: 672-674
• 59 Bando E. et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-262
• 60 Kodera Y. et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72: 60-64 ; discussion 64–65
• 61 Bentrem D. et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005; 12: 347-353
• 62 Ribeiro Jr U. et al. Does the intraoperative peritoneal lavage cytology add prognostic information in patients with potentially curative gastric resection?. J Gastrointest Surg 2006; 10: 170-176 , discussion 176–177
• 63 De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol 2014; 110: 291-297
• 64 Satoh S. et al. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer 2012; 15: 61-69
• 65 Lorenzen S. et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol 2010; 17: 2733-2739
• 66 Badgwell B. et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?. Ann Surg Oncol 2008; 15: 2684-2691
• 67 Okabe H. et al. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 2009; 16: 3227-3236
• 68 Mezhir JJ. et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Indian J Surg Oncol 2011; 2: 16-23
• 69 Yang XJ. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18: 1575-1581
• 70 Kuramoto M. et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009; 250: 242-246
• 71 Sarela AI. et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 2006; 191: 134-138
• 72 Power DG. et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 2009; 208: 173-178
• 73 Deng K. et al. Prognostic Significance of Molecular Analysis of Peritoneal Fluid for Patients with Gastric Cancer: A Meta-Analysis. PLoS One 2016; 11: e0151608
• 74 Fujii S. et al. Carcinoembryonic antigen mRNA in abdominal cavity as a useful predictor of peritoneal recurrence of gastric cancer with serosal exposure. J Exp Clin Cancer Res 2002; 21: 547-553
• 75 Fujiwara Y. et al. The clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids in gastric cancer with clinical serosal invasion: a prospective, multicenter study. Surgery 2014; 155: 417-423
• 76 Fukumoto Y. et al. Detection of cancer cells and gene expression of cytokines in the peritoneal cavity in patients with gastric cancer. Gastric Cancer 2006; 9: 271-276
• 77 Hara M. et al. Comparative analysis of intraperitoneal minimal free cancer cells between colorectal and gastric cancer patients using quantitative RT-PCR: possible reason for rare peritoneal recurrence in colorectal cancer. Clin Exp Metastasis 2007; 24: 179-189
• 78 Horikawa M. et al. Clinical significance of intraperitoneal CD44 mRNA levels of magnetically separated CD45-negative EpCAM-positive cells for peritoneal recurrence and prognosis in stage II and III gastric cancer patients. Oncol Rep 2011; 25: 1413-1420
• 79 Ishii T. et al. Rapid genetic diagnosis with the transcription-reverse transcription concerted reaction system for cancer micrometastasis. Ann Surg Oncol 2004; 11: 778-785
• 80 Ito S. et al. Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer 2005; 93: 986-992
• 81 Katsuragi K. et al. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer 2007; 97: 550-556
• 82 Kodera Y. et al. Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of followup. J Am Coll Surg 2006; 202: 231-236
• 83 Li Z. et al. Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients. Tumour Biol 2014; 35: 3463-3470
• 84 Miyagawa K. et al. Overexpression of RegIV in peritoneal dissemination of gastric cancer and its potential as A novel marker for the detection of peritoneal micrometastasis. Anticancer Res 2008; 28: 1169-1179
• 85 Mori K. et al. Detection of minimal gastric cancer cells in peritoneal washings by focused microarray analysis with multiple markers: clinical implications. Ann Surg Oncol 2007; 14: 1694-1702
• 86 Nakanishi H. et al. Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol 1999; 43: S32-S36
• 87 Okada K. et al. Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol 2012; 105: 780-785
• 88 Oyama K. et al. Prognostic significance of peritoneal minimal residual disease in gastric cancer detected by reverse transcription-polymerase chain reaction. Br J Surg 2004; 91: 435-443
• 89 Rossi Del Monte S. et al. Free peritoneal tumor cells detection in gastric and colorectal cancer patients. J Surg Oncol 2012; 106: 17-23
• 90 Jeon CH, Kim IH, Chae HD. Prognostic value of genetic detection using CEA and MAGE in peritoneal washes with gastric carcinoma after curative resection: result of a 3-year follow- up. Medicine (Baltimore) 2014; 93: e83
• 91 Lee SR. et al. Prognostic significance of quantitative carcinoembryonic antigen and cytokeratin 20 mRNA detection in peritoneal washes of gastric cancer patients. Hepatogastroenterology 2013; 60: 1237-1244
• 92 Nakabayashi K. et al. Rapid detection of CEA mRNA in peritoneal washes using One-Step Nucleic acid Amplification (OSNA) for gastric cancer patients. Clin Chim Acta 2015; 439: 137-142
• 93 Satoh Y. et al. Analysis for the combination expression of CK20, FABP1 and MUC2 is sensitive for the prediction of peritoneal recurrence in gastric cancer. Jpn J Clin Oncol 2012; 42: 148-152
• 94 Sugita Y. et al. Quantitative molecular diagnosis of peritoneal lavage fluid for prediction of peritoneal recurrence in gastric cancer. Int J Oncol 2003; 23: 1419-1423
• 95 Takata A. et al. Prognostic value of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer. World J Surg 2014; 38: 1107-1111
• 96 Takebayashi K. et al. Surgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer. Ann Surg Oncol 2014; 21: 1991-1997
• 97 Tamura N, Iinuma H, Takada T. Prospective study of the quantitative carcinoembryonic antigen and cytokeratin 20 mRNA detection in peritoneal washes to predict peritoneal recurrence in gastric carcinoma patients. Oncol Rep 2007; 17: 667-672
• 98 Tamura S. et al. Prognostic information derived from RT-PCR analysis of peritoneal fluid in gastric cancer patients: results from a prospective multicenter clinical trial. J Surg Oncol 2014; 109: 75-80
• 99 Tokuda K. et al. Clinical significance of CEA-mRNA expression in peritoneal lavage fluid from patients with gastric cancer. Int J Mol Med 2003; 11: 79-84
• 100 Wang JY. et al. Gastric cancer cell detection in peritoneal lavage: RT-PCR for carcinoembryonic antigen transcripts versus the combined cytology with peritoneal carcinoembryonic antigen levels. Cancer Lett 2005; 223: 129-135
• 101 Wong J. et al. Rt-PCR increases detection of submicroscopic peritoneal metastases in gastric cancer and has prognostic significance. J Gastrointest Surg 2012; 16: 889-896 ; discussion 896
• 102 Yabusaki N. et al. Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Mol Clin Oncol 2015; 3: 435-441
• 103 Yoneda A. et al. The detection of gastric cancer cells in intraoperative peritoneal lavage using the reverse transcription--loop-mediated isothermal amplification method. J Surg Res 2014; 187: e1-e6
• 104 Yonemura Y. et al. Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res 2001; 7: 1647-1653
• 105 Cotte E. et al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. Eur J Surg Oncol 2013; 39: 707-714
• 106 Munasinghe A. et al. The incremental benefit of two quadrant lavage for peritoneal cytology at staging laparoscopy for oesophagogastric adenocarcinoma. Surg Endosc 2013; 27: 4049-4053
• 107 Higaki E. et al. Intraoperative peritoneal lavage cytology offers prognostic significance for gastric cancer patients with curative resection. Cancer Sci 2017; 108: 978-986
• 108 Kanetaka K. et al. Clinical significance of carcinoembryonic antigen in peritoneal lavage from patients with gastric cancer. Surgery 2013; 154: 563-572
• 109 Ozer I. et al. Presence of free cancer cells in the peritoneal cavity of patients who underwent curative gastrectomy with lymph node dissection. Hepatogastroenterology 2012; 59: 1657-1660
• 110 Liu L. et al. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer Prev 2012; 13: 3089-3097
• 111 Takahashi R. et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003; 64: 266-274
• 112 Wang X. et al. VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer. J Surg Oncol 2010; 102: 325-330
• 113 Zhou Y. et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol 2010; 31: 549-558
• 114 Aoyagi K. et al. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005; 8: 155-163
• 115 Bazas VM. et al. Relation between cell-to-cell adhesion and angiogenesis and clinico- morphological prognostic factors in patients with gastric cancer. Exp Oncol 2008; 30: 235-239
• 116 Ding S. et al. Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep 2007; 17: 369-375
• 117 Fondevila C. et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90: 206-215
• 118 Ikeguchi M. et al. The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer. Langenbecks Arch Surg 1999; 384: 264-270
• 119 Kakeji Y. et al. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 2002; 21: 125-129
• 120 Vidal O. et al. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg 2008; 12: 1005-1014
• 121 Zhang L. et al. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 2006; 12: 3970-3976
• 122 Maeda K. et al. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 1999; 86: 566-571
• 123 Shi H. et al. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 2003; 9: 1421-1426
• 124 Wang J. et al. Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011; 26: 23-32
• 125 Ozdemir F. et al. The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res 2006; 25: 83-88
• 126 Yang Q. et al. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken) 2010; 293: 2012-2019
• 127 Lee SJ. et al. No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat 2009; 41: 218-223
• 128 Urano N. et al. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer 2006; 9: 44-49
• 129 Joo YE. et al. The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med 2002; 17: 211-219
• 130 Anastasios R. et al. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 2002; 13: 376
• 131 Choi JH. et al. Correlation of vascular endothelial growth factor-D expression and VEGFR-3- positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci 2008; 23: 592-597
• 132 Da MX. et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res 2008; 39: 92-99
• 133 Deguchi K. et al. Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res 2010; 30: 2361-2366
• 134 Deng J. et al. Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy. Surgery 2009; 146: 896-905
• 135 Gou HF. et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res 2011; 30: 14
• 136 Han FH. et al. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 2010; 36: 1172-1179
• 137 Juttner S. et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-240
• 138 Kolev Y. et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 2007; 14: 2738-2747
• 139 Lieto E. et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15: 69-79
• 140 Maeda K. et al. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer 1997; 74: 545-550
• 141 Shida A. et al. Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg 2005; 29: 1600-1607
• 142 Skarlos DV. et al. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res 2007; 27: 2973-2983
• 143 Takahashi A. et al. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 2002; 62: 121-127
• 144 Tsutsumi S. et al. Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer. Hepatogastroenterology 2005; 52: 629-632
• 145 Vidal O. et al. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 2009; 96: 1443-1451
• 146 Wang TB. et al. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13: 1794-1797 ; discussion 1797–1798
• 147 Yonemura Y. et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999; 5: 1823-1829
• 148 Yoshikawa T. et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000; 153: 7-12
• 149 Kimura H. et al. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol 2001; 76: 31-36
• 150 Zhang CT. et al. Prognostic value of Muc5AC in gastric cancer: A meta-analysis. World J Gastroenterol 2015; 21: 10453-10460
• 151 Baldus SE. et al. Correlation of MUC5AC immunoreactivity with histopathological subtypes and prognosis of gastric carcinoma. Ann Surg Oncol 2002; 9: 887-893
• 152 Ilhan O. et al. Prognostic significance of MUC1, MUC2 and MUC5AC expressions in gastric carcinoma. Turk J Gastroenterol 2010; 21: 345-352
• 153 Kocer B. et al. Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci 2004; 49: 954-964
• 154 Lee HS. et al. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 2001; 92: 1427-1434
• 155 Shiratsu K, Higuchi K, Nakayama J. Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach. Cancer Sci 2014; 105: 126-133
• 156 Suh YS. et al. The combined expression of metaplasia biomarkers predicts the prognosis of gastric cancer. Ann Surg Oncol 2012; 19: 1240-1249
• 157 Tajima Y. et al. Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions. Oncology 2001; 61: 212-220
• 158 Wang JY. et al. Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas. J Surg Oncol 2003; 83: 253-260
• 159 Wang RQ, Fang DC. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol 2003; 56: 378-384
• 160 Kim DH. et al. Mucin expression in gastric cancer: reappraisal of its clinicopathologic and prognostic significance. Arch Pathol Lab Med 2013; 137: 1047-1053
• 161 Kim SM. et al. Decreased Muc5AC expression is associated with poor prognosis in gastric cancer. Int J Cancer 2014; 134: 114-124
• 162 Ji K. et al. Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2016; 95: e2641
• 163 Choi E. et al. Implication of Leptin-Signaling Proteins and Epstein-Barr Virus in Gastric Carcinomas. PLoS One 2015; 10: e0130839
• 164 Choi JH. et al. Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. Apmis 2006; 114: 619-625
• 165 Deng J. et al. STAT3 is associated with lymph node metastasis in gastric cancer. Tumour Biol 2013; 34: 2791-2800
• 166 Deng JY. et al. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 2010; 16: 5380-5387
• 167 Gao F. et al. Correlation of epigenetic aberrance with STAT3 signaling pathway in gastric carcinogenesis. Dig Dis Sci 2012; 57: 2055-2062
• 168 Gong W. et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005; 11: 1386-1393
• 169 Hino R. et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009; 69: 2766-2774
• 170 Inokuchi M. et al. Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Exp Ther Med 2011; 2: 251-256
• 171 Lee J. et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. Apmis 2009; 117: 598-606
• 172 Liu Y. et al. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer. Med Oncol 2015; 32: 404
• 173 Song YY. et al. STAT3, p-STAT3 and HIF-1alpha are associated with vasculogenic mimicry and impact on survival in gastric adenocarcinoma. Oncol Lett 2014; 8: 431-437
• 174 Wei ZW. et al. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Lett 2015; 359: 335-343
• 175 Woo S. et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with better prognosis, cell proliferation and hypoxia-inducible factor-1alpha in human gastric cancer. Pathobiology 2011; 78: 295-301
• 176 Wu LJ. et al. STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer. Int J Clin Exp Pathol 2014; 7: 1140-1146
• 177 Xiong H. et al. A positive feedback loop between STAT3 and cyclooxygenase-2 gene may contribute to Helicobacter pylori-associated human gastric tumorigenesis. Int J Cancer 2014; 134: 2030-2040
• 178 Yakata Y. et al. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol 2007; 30: 437-442
• 179 Yu LF. et al. Constitutive activation and clinical significance of Stat3 in human gastric cancer tissues and cell lines. Zhonghua Yi Xue Za Zhi 2004; 84: 2064-2069
• 180 Xiong H. et al. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl) 2012; 90: 1037-1046
• 181 Zhang JG, Zhao J, Xin Y. Significance and relationship between Cripto-1 and p-STAT3 expression in gastric cancer and precancerous lesions. World J Gastroenterol 2010; 16: 571-577
• 182 Cong LTL, Zhao J. et al. Active level of p-stat3 and expression of p53 and C-erb-B2 in gastric cancer. Chin J Lab Diagn 2013; 17: 896-899
• 183 Gong DP, NAME ZZ, Lu SM. et al. Relationship between Helicobacter pylori infection and expressions of p-stat3, Bcl-2, Mcl-1 in gastric carcinoma. Med Philos 2015; 36: 70-73
• 184 Lu SM, NAME CM, Liu LN. et al. Relationship between STAT3 activation and epithelialmesenchymal transition in gastric carcinoma. World Chin J Digestol 2013; 21: 2748-2753
• 185 Qiao YY, NAME JM, Ma XM. et al. Expression of JAK1, p-stat3 and bcl-2 in gastric cancer and their significance. Cancer Res Prevent Treat 2009; 36: 657-661
• 186 Deng N. et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012; 61: 673-684
• 187 Di Bartolomeo M. et al. Osteopontin, E-cadherin, and beta-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer 2016; 19: 412-420
• 188 Fristedt R. et al. Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol 2016; 7: 848-859
• 189 Jagadesham VP. et al. Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Surg 2017; 104: 401-407
• 190 Kawazoe A. et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer 2017; 20: 407-415
• 191 Schlosser HA. et al. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology 2016; 5: e1100789
• 192 Boger C. et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016; 7: 24269-24283
• 193 Huang Z. et al. Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma. Asian Pac J Cancer Prev 2014; 15: 989-997
• 194 Yan P. et al. High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer. Asian Pac J Cancer Prev 2014; 15: 8923-8929
• 195 Zhang J. et al. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides 2014; 61: 7-11
• 196 Kaplan MA. et al. Relationship between serum soluble vascular adhesion protein-1 level and gastric cancer prognosis. Oncol Res Treat 2014; 37: 340-344
• 197 Deng Q. et al. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China. Int J Clin Exp Pathol 2014; 7: 8312-8321
• 198 Mu YP. et al. Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features and prognosis in gastric cancer. Asian Pac J Cancer Prev 2014; 15: 8893-8900
• 199 Jiang W. et al. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. Surg Oncol 2015; 24: 220-225
• 200 Yoshikawa T. et al. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study. Ann Surg Oncol 2014; 21 (Suppl. 03) S385-S389
• 201 Hu YY. et al. Diagnostic performance of magnifying narrow-band imaging for early gastric cancer: A meta-analysis. World J Gastroenterol 2015; 21: 7884-7894
• 202 Liu H. et al. Evaluating the diagnoses of gastric antral lesions using magnifying endoscopy with narrow-band imaging in a Chinese population. Dig Dis Sci 2014; 59: 1513-1519
• 203 Yao K. et al. Diagnostic performance and limitations of magnifying narrow-band imaging in screening endoscopy of early gastric cancer: a prospective multicenter feasibility study. Gastric Cancer 2014; 17: 669-679
• 204 Kanesaka T. et al. Dense-type crypt opening seen on magnifying endoscopy with narrow-band imaging is a feature of gastric adenoma. Dig Endosc 2014; 26: 57-62
• 205 Tao G. et al. Enhanced magnifying endoscopy for differential diagnosis of superficial gastric lesions identified with white-light endoscopy. Gastric Cancer 2014; 17: 122-129
• 206 Horiuchi H. et al. Magnifying endoscopy combined with narrow band imaging may help to predict neoplasia coexisting with gastric hyperplastic polyps. Scand J Gastroenterol 2013; 48: 626-632
• 207 Maki S. et al. Magnifying endoscopy with narrow-band imaging is useful in the differential diagnosis between low-grade adenoma and early cancer of superficial elevated gastric lesions. Gastric Cancer 2013; 16: 140-146
• 208 Miwa K. et al. Can magnifying endoscopy with narrow band imaging be useful for low grade adenomas in preoperative biopsy specimens?. Gastric Cancer 2012; 15: 170-178
• 209 Tsuji Y. et al. Magnifying endoscopy with narrow-band imaging helps determine the management of gastric adenomas. Gastric Cancer 2012; 15: 414-418
• 210 Li HY. et al. Application of magnifying endoscopy with narrow-band imaging in diagnosing gastric lesions: a prospective study. Gastrointest Endosc 2012; 76: 1124-1132
• 211 Ezoe Y. et al. Magnifying narrowband imaging is more accurate than conventional white- light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 2011; 141: 2017-2025 e3
• 212 Nonaka K. et al. Prospective study of the evaluation of the usefulness of tumor typing by narrow band imaging for the differential diagnosis of gastric adenoma and well-differentiated adenocarcinoma. Dig Endosc 2011; 23: 146-152
• 213 Ezoe Y. et al. Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study. Gastrointest Endosc 2010; 71: 477-484
• 214 Kato M. et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 2010; 72: 523-529
• 215 Yao K. et al. White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma. Gastrointest Endosc 2008; 68: 574-580
• 216 Long D. et al. Systematic review of partial hepatic resection to treat hepatic metastases in patients with gastric cancer. Medicine (Baltimore) 2016; 95: e5235
• 217 Ang TL. et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J Gastroenterol Hepatol 2015; 27: 1473-1478
• 218 Dutta AK. et al. Narrow band imaging versus white light gastroscopy in detecting potentially premalignant gastric lesions: a randomized prospective crossover study. Indian J Gastroenterol 2013; 32: 37-42
• 219 So J. et al. Endoscopic tri-modal imaging improves detection of gastric intestinal metaplasia among a high-risk patient population in Singapore. Dig Dis Sci 2013; 58: 3566-3575
• 220 Lee BE. et al. Acetic acid-indigo carmine chromoendoscopy for delineating early gastric cancers: its usefulness according to histological type. BMC Gastroenterol 2010; 10: 97
• 221 Zhang J, Guo SB, Duan ZJ. Application of magnifying narrow-band imaging endoscopy for diagnosis of early gastric cancer and precancerous lesion. BMC Gastroenterol 2011; 11: 135
• 222 Facciorusso A. et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: A meta-analysis. World J Gastrointest Endosc 2014; 6: 555-563
• 223 Min BH. et al. Clinical outcomes of endoscopic submucosal dissection (ESD) for treating early gastric cancer: comparison with endoscopic mucosal resection after circumferential precutting (EMR-P). Dig Liver Dis 2009; 41: 201-209
• 224 Oka S. et al. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc 2006; 64: 877-883
• 225 Catalano F. et al. The modern treatment of early gastric cancer: our experience in an Italian cohort. Surg Endosc 2009; 23: 1581-1586
• 226 Odashima M. et al. Improved Curative Resection Rates of Early Gastric Cancers By Endoscopic Mucosal Resection (EMR) Using Endoscopic Submucosal Dissection Method (ESD). Gastrointestinal Endoscopy 2006; 63: AB187
• 227 Hoteya S. et al The Safety and Efficacy of the Endoscopic Submucosal Dissection for Early Gastric Cancers, Compared with&#xa. Conventional Endoscopic Mucosal Resection . Gastrointestinal Endoscopy 2007; 65: AB358
• 228 Hoteya S. et al. Clinical advantages of endoscopic submucosal dissection for gastric cancers in remnant stomach surpass conventional endoscopic mucosal resection. Dig Endosc 2010; 22: 17-20
• 229 Nakamoto S. et al. Indications for the use of endoscopic mucosal resection for early gastric cancer in Japan: a comparative study with endoscopic submucosal dissection. Endoscopy 2009; 41: 746-750
• 230 Watanabe T. et al. Gastric mucosal cancer smaller than 7mm can be treated with conventional endoscopic mucosal resection as effectively as with endoscopic submucosal dissection. Hepatogastroenterology 2010; 57: 668-673
• 231 Tanabe S. et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center. Gastric Cancer 2014; 17: 130-136
• 232 Oda I. et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer 2006; 9: 262-270
• 233 Park YM. et al. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc 2011; 25: 2666-2677
• 234 Kwi-Sook Choi MD, Hwoon-Yong Jung MD, Kee Don Choi MD. et al. Endoscopic Submucosal Dissection for Gastric Tumors: Complete Resection Rate, Resection Time and Complications in Comparison with Endoscopic Mucosal Resection after Circumferential Mucosal Incision with a Needle Knife. Clin Endosc 2006; 32: 326-332
• 235 Shimura T. et al. Advantages of endoscopic submucosal dissection over conventional endoscopic mucosal resection. J Gastroenterol Hepatol 2007; 22: 821-826
• 236 Hirasaki S. et al. Treatment of gastric remnant cancer post distal gastrectomy by endoscopic submucosal dissection using an insulation- tipped diathermic knife. World J Gastroenterol 2008; 14: 2550-2555
• 237 Hoteya S. et al. Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection. J Gastroenterol Hepatol 2009; 24: 1102-1106
• 238 Yokoi C. et al. Endoscopic submucosal dissection allows curative resection of locally recurrent early gastric cancer after prior endoscopic mucosal resection. Gastrointest Endosc 2006; 64: 212-218
• 239 Best LMJ, Mughal M, Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database Syst Rev 2016; 3: CD011389
• 240 Aoyama T. et al. Randomized comparison of surgical stress and the nutritional status between laparoscopy-assisted and open distal gastrectomy for gastric cancer. Ann Surg Oncol 2014; 21: 1983-1990
• 241 Cai J. et al. A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer. Dig Surg 2011; 28: 331-337
• 242 Chen HuJ. et al. Preliminary experience of fast-track surgery combined with laparoscopy- assisted radical distal gastrectomy for gastric cancer. J Gastrointest Surg 2012; 16: 1830-1839
• 243 Deng HJ. et al. Effects of laparoscopy-assisted distal gastrectomy on C-reactive protein and visceral proteins in patients with gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 1596-1598
• 244 Hayashi H. et al. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 2005; 19: 1172-1176
• 245 Hu Y. et al. Laparoscopic D2 distal gastrectomy versus conventional open surgery for advanced gastric cancer: The safety analysis from a multicenter prospective randomized controlled trial in China (CLASS-01 Trial). 2015 American Society of Clinical Oncology
• 246 Huscher CG. et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg 2005; 241: 232-237
• 247 Kim YW. et al. Result of clinical study on feasibility of laparoscopy-assisted D2 distal gastrectomy to treat advanced gastric cancer (COACT_1001). 2013 , American Society of Clinical Oncology
• 248 Lee HJ. et al. Morbidity and mortality after laparoscopy-assisted and open distal gastrectomy for stage I gastric cancer: Results from a multicenter randomized controlled trial (KLASS-01). 2015 American Society of Clinical Oncology
• 249 Fujii K. et al. T lymphocyte subsets and Th1/Th2 balance after laparoscopy-assisted distal gastrectomy. Surgical Endoscopy And Other Interventional Techniques 2003; 17: 1440-1444
• 250 Lee JH, Han HS. A prospective randomized study comparing open vs laparoscopy- assisted distal gastrectomy in early gastric cancer: early results. Surgical Endoscopy And Other Interventional Techniques 2005; 19: 168-173
• 251 Sakuramoto S. et al. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial. Surgical endoscopy 2013; 27: 1695-1705
• 252 Takiguchi S. et al. Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World journal of surgery 2013; 37: 2379-2386
• 253 Cui M. et al. A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer. Med Oncol 2015; 32: 241
• 254 Hu Y. et al. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology 2016; 34: 1350-1357
• 255 Park Y. et al. Laparoscopy-Assisted versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: Results from a Randomized Phase II Multicenter Clinical Trial (COACT 1001). Ann Surg 2018; 267: 638-645
• 256 Lee JH. et al. Clinical impact of tumor infiltration at the transected surgical margin during gastric cancer surgery. J Surg Oncol 2012; 106: 772-776
• 257 Woo JW. et al. Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection. World J Surg 2014; 38: 439-446
• 258 Squires MH. et al. Is it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol 2015; 22: 1243-1251
• 259 Liang Y. et al. Prognostic value of surgical margin status in gastric cancer patients. ANZ J Surg 2015; 85: 678-684
• 260 Postlewait LM. et al. The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multi-institutional study of the US Gastric Cancer Collaborative. J Surg Oncol 2015; 112: 203-207
• 261 Stiekema J. et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol 2014; 21: 1107-1114
• 262 Stiekema J. et al. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study. Ann Surg Oncol 2015; 22: 581-588
• 263 Mohammad NH. et al. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Rev 2015; 34: 429-441
• 264 Ajani JA. et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. Journal of Clinical Oncology 2005; 23: 5660-5667
• 265 Al-Batran SE. et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). European Journal of Cancer 2013; 49: 835-842
• 266 Cullinan SA. et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. Jama 1985; 253: 2061-2067
• 267 Douglass Jr HO. et al. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). Journal of Clinical Oncology 1984; 2: 1372-1381
• 268 Guimbaud R. et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. Journal of Clinical Oncology 2014; 32: 3520-3526
• 269 Kim NK. et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5- fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818
• 270 Kim T. et al. A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-FU (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC). European Journal of Cancer 2001; 37: S314
• 271 Koizumi W. et al. Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. Anticancer research 2004; 24: 2465-2470
• 272 (KRGCGC), K.R.G.f.C.o.G.C. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4 ’-epirubicin (FPEPIR). Anticancer Research 1992; 12: 1983-1988
• 273 Li XD. et al. Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World journal of gastroenterology 2011; 17: 1082
• 274 Lin R. et al. Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC). Journal of Clinical Oncology 2009; 27: e15642-e15642
• 275 Maiello E. et al. Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomized phase II trial of the Gruppo Oncologico Dell’Italia Meridionale. Journal of Clinical Oncology 2011; 29 (Suppl. 04) 97
• 276 Park S. et al. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of oncology 2008; 19: 729-733
• 277 Roth A. et al. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori 1999; 85: 234-238
• 278 Roth AD. et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology 2007; 25: 3217-3223
• 279 Thuss-Patience PC. et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. Journal of Clinical Oncology 2005; 23: 494-501
• 280 Van Cutsem E. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of clinical oncology 2006; 24: 4991-4997
• 281 Van Cutsem E. et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of Oncology 2014; 26: 149-156
• 282 Vanhoefer U. et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology 2000; 18: 2648-2657
• 283 Wang J. et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric cancer 2016; 19: 234-244
• 284 Yun J. et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. European Journal of Cancer 2010; 46: 885-891
• 285 Bang YJ. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321
• 286 Lorenzen S. et al. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. British Journal of Cancer 2013; 108: 519-526
• 287 Bajetta E. et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol 2014; 25: 1373-1378
• 288 Al-Batran SE. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016; 17: 1697-1708
• 289 Phillips BE. et al. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus 2013; 26: 299-304
• 290 Becker K. et al. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 2012; 256: 1002-1007
• 291 Ott K. et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor. Langenbecks Arch Surg 2013; 398: 239-249
• 292 Koh YW. et al. Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy. Am J Surg Pathol 2013; 37: 1022-1029
• 293 Schmidt T. et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer 2014; 110: 1712-1720
• 294 Smalley SR. et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-2333
• 295 Stessin AM. et al. Does adjuvant radiotherapy benefit patients with diffuse-type gastric cancer? Results from the Surveillance, Epidemiology, and End Results database. Cancer 2014; 120: 3562-3568
• 296 Sun J. et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 2012; 12: 526
• 297 Koga S. et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988; 61: 232-237
• 298 Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994; 73: 2048-2052
• 299 Fujimura T. et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World journal of surgery 1994; 18: 150-155
• 300 Ikeguchi M. et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. The European journal of surgery = Acta chirurgica 1995; 161: 581-586
• 301 Fujimoto S. et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-534
• 302 Yonemura Y. et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepato-gastroenterology 2000; 48: 1776-1782
• 303 Zuo Y. et al. Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2004; 26: 247-249
• 304 Wei G. et al. Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai zheng= Aizheng= Chinese journal of cancer 2005; 24: 478-482
• 305 Zhang G. et al. Application of hyperthermic intraoperative intraperitoneal chemotherapy in patients with gastric cancer. Zhonghua wei chang wai ke za zhi= Chinese journal of gastrointestinal surgery 2007; 10: 362-364
• 306 Deng H. et al. Clinical application of perioperative continuous hyperthermic peritoneal perfusion chemotherapy for gastric cancer. Nan fang yi ke da xue xue bao= Journal of Southern Medical University 2009; 29: 295-297
• 307 Mi DH. et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia 2013; 29: 156-167
• 308 Chen J. et al. Clinical application of postoperative intraperitoneal hyperthermic perfusion combined with venoclysis for gastric cancer. Chinese Journal of Cancer Prevention and Treatment 2006; 13: 937-938
• 309 Chen S. et al. Efficacy of intraoperative hyperthermic intraperitoneal chemotherapy for patients with advanced gastric carcinoma. J Youjiang Med Coll Nation 2005; 27: 357
• 310 Chen Z. et al. Positive results of therapy of gastric cancer patients after operation by intraperitoneal hyperthermic chemotherapy. Zhonghua Shiyong Yixue 2001; 3: 39-40
• 311 Jin Y. Efficacy of intraoperative hyperthermic intraperitoneal chemotherapy for patients with advanced gastric carcinoma. Zhejiang J Clin Med 2007; 9: 357-358
• 312 Wang F, Hou A, Peng Z. Clinical study of hypotonic intraoperative intraperitoneal chemohyperthermia for gastric cancer. Clin J Med Offic 2006; 34: 17-19
• 313 Wang M. et al. Clinical application of intraperitoneal hyperthermia chemoperfusion in the operation for the advanced gastric cancer. World J Med Today 2002; 3: 293-294
• 314 Wang S. The analysis for curative effect of intraoperative hyperthermic intraperitoneal chemotherapy combined with postoperative veins chemotherapy. Chron Pathem J (China) 2010; 12: 404-405
• 315 Ye L. et al. Application of intraperitoneal peirtoneal hyperthermia chemoperfusion in advanced gastric cancer. Int Med Health Guid News (China) 2007; 13: 29-31
• 316 Yonemura Y. et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World journal of surgery 1995; 19: 450-454
• 317 Yonemura Y. et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepato-gastroenterology 2001; 48: 1776-1782
• 318 Zhan H. et al. Efficacy of intraoperative hyperthermic peritoneal perfusion on 60 patients with advanced gastric carcinoma. Chinese Journal of Clinical Oncology 2010; 37: 229-231
• 319 Zhang W. et al. Clinical study of intraoperative hyperthermic intraperitoneal chemotherapy for preventing the peritoneal recurrence of advanced gastric carcinoma. Shanxi Med J 1998; 27: 67-69
• 320 Sun J. et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2013; 13: 577
• 321 Pang X. et al. Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumour Biol 2014; 35: 387-396
• 322 Coccolini F. et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 2014; 40: 12-26
• 323 Desiderio J. et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 2017; 79: 1-14
• 324 Rudloff U. et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy(HIPEC) on outcome of patients with peritoneal carcinomatosis of gastricorigin: results of the GYMSSA trial. Journal of Surgical Oncology 2014; 110: 275-284
• 325 Wagner AD. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017; 8: CD004064
• 326 Thuss-Patience PC. et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314
• 327 Kang JH. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518
• 328 Janowitz T. et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer 2016; 114: 381-387
• 329 Ochenduszko S. et al. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2- negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Med Oncol 2015; 32: 242
• 330 Fuchs CS. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
• 331 Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Med Oncol 2014; 31: 906
• 332 Gubanski M. et al. Randomized phase II study of sequential docetaxel and irinotecan with 5- fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010; 13: 155-161
• 333 Shah MA. et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol 2015; 33: 3874-3879
• 334 Hironaka S. et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013; 31: 4438-4444
• 335 Allum WH. et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449-1472
• 336 Dassen AE. et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009; 35: 449-455
• 337 Chowdhury FU, Bradley KM, Gleeson FV. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma. Clin Radiol 2008; 63: 1297-1309
• 338 Lerut T. Clinical Practice Guidelines Upper Gastrointestinal Cancer – update. KCE 2012
• 339 Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review. BMC Gastroenterol 2011; 11: 19
• 340 Leake PA. et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer 2012; 15 (Suppl. 01) S38-S47
• 341 de Graaf GW. et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007; 33: 988-992
• 342 Nieveen van Dijkum EJ. et al. The efficacy of laparoscopic staging in patients with upper gastrointestinal tumors. Cancer 1997; 79: 1315-1319
• 343 Nath J. et al. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg 2008; 95: 721-726
• 344 Luketich JD. et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68: 1133-1136 ; discussion 1136–1137
• 345 Krasna MJ. et al. CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg 2001; 71: 1073-1079
• 346 Krasna MJ. et al. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons . Ann Thorac Surg 1995; 60: 1337-1340
• 347 Network SIG. Management of oesophageal and gastric cancer. A national clinical guideline. SIGN 2006
• 348 Mortensen MB. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography. Dan Med J 2012; 59: B4568
• 349 Mahadevan D. et al. Laparoscopic staging in gastric cancer: An essential step in its management. J Minim Access Surg 2010; 6: 111-113
• 350 Leake PA. et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 2012; 15 (Suppl. 01) S27-S37
• 351 Smalley SR. et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002; 52: 283-293
• 352 Willett CG, NAME GL. Stomach in: Perez and Brady’sprinciples and practice of radiation oncology. 2007. (5^th ed.)
• 353 Fiore D. et al. Multimodal imaging of esophagus and cardia cancer before and after treatment. Radiol Med 2006; 111: 804-817
• 354 Kumbasar B. Carcinoma of esophagus: radiologic diagnosis and staging. Eur J Radiol 2002; 42: 170-180
• 355 Bachmann MO. et al. Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002; 89: 914-922
• 356 Birkmeyer JD. et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137
• 357 Health., D.o. Guidance on Commissioning Cancer Services: Improving Outcomes in Upper Gastro-Intestinal Cancers. 2001: 1e96
• 358 Sutton DN, Wayman J, Griffin SM. Learning curve for oesophageal cancer surgery. Br J Surg 1998; 85: 1399-1402
• 359 Parikh D. et al. D2 gastrectomy: lessons from a prospective audit of the learning curve. Br J Surg 1996; 83: 1595-1599
• 360 AUGIS, A.o.U.G.S.o.G.B.a.I., and Clinical Services Committee. AUGIS Recommendations on Minimum Volumes 2010. AUGIS Guidance on Minimum Surgeon Volumes 2010. 2011 http://www.augis.org
• 361 Waddell T. et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi57-vi63
• 362 Dikken JL. et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg 2013; 100: 83-94
• 363 Omloo JM. et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000 ; discussion 1000–1001
• 364 Sasako M. et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644-651
• 365 Bonenkamp JJ. et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914
• 366 Cuschieri A. et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530
• 367 Songun I. et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449
• 368 Degiuli M. et al. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004; 90: 1727-1732
• 369 Cuschieri A. et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995-999
• 370 Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998; 123: 573-578
• 371 Roviello F. et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol 2002; 9: 894-900
• 372 Yildirim E, Celen O, Berberoglu U. The Turkish experience with curative gastrectomies for gastric carcinoma: is D2 dissection worthwhile?. J Am Coll Surg 2001; 192: 25-37
• 373 Robertson CS. et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994; 220: 176-182
• 374 Wu CW. et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-315
• 375 Sasako M. et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462
• 376 Yonemura Y. et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008; 13: 132-137
• 377 Lamb P. et al. Gastric cancer surgery – a balance of risk and radicality. Ann R Coll Surg Engl 2008; 90: 235-242
• 378 Sano T. Tailoring treatments for curable gastric cancer. Br J Surg 2007; 94: 263-264
• 379 Sobin L, NAME GM, Wittekind C. TNM Classification of Malignant Tumours. 7th. edition. Oxford: Wiley-Blackwell; 2009
• 380 Compton C. et al. „AJCC cancer staging manual.“. 2010. Chapter 14 143-164
• 381 Jiang L. et al. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis. J Surg Oncol 2013; 107: 807-814
• 382 Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007; 14: 317-328
• 383 Karpeh MS. et al. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1038 patients. Ann Surg 2000; 232: 362-371
• 384 Moehler M. et al. German S3-guideline „Diagnosis and treatment of esophagogastric cancer“. Z Gastroenterol 2011; 49: 461-531
• 385 Ohri N. et al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta- analysis. Int J Radiat Oncol Biol Phys 2013; 86: 330-335
• 386 Bamias A. et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010; 65: 1009-1021
• 387 Lee J. et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273
• 388 Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008: CD006145
• 389 Markes M, Brockow T, Resch KL. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2006: CD005001
• 390 Milne HM. et al. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2008; 108: 279-288
• 391 Bozzetti F. et al. The nutritional risk in oncology: a study of 1453 cancer outpatients. Support Care Cancer 2012; 20: 1919-1928
• 392 Gavazzi C. et al. Importance of early nutritional screening in patients with gastric cancer. Br J Nutr 2011; 106: 1773-1778
• 393 Kondrup J. et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22: 415-421
• 394 Ryu SW, Kim IH. Comparison of different nutritional assessments in detecting malnutrition among gastric cancer patients. World J Gastroenterol 2010; 16: 3310-3317
• 395 Prado CM. et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920-2926
• 396 Jang RW. et al. Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract 2014; 10: e335-e341
• 397 Richards CH. et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One 2012; 7: e41883
• 398 Weimann A. et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr 2017; 36: 623-650
• 399 Mabvuure NT, Roman A, Khan OA. Enteral immunonutrition versus standard enteral nutrition for patients undergoing oesophagogastric resection for cancer. Int J Surg 2013; 11: 122-127
• 400 Osland E. et al. Effect of timing of pharmaconutrition (immunonutrition) administration on outcomes of elective surgery for gastrointestinal malignancies: a systematic review and meta- analysis. J Parenter Enteral Nutr 2014; 38: 53-69
• 401 Jie B. et al. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition 2012; 28: 1022-1027
• 402 Hill GL. Impact of nutritional support on the clinical outcome of the surgical patient. Clin Nutr 1994; 13: 331-340
• 403 Bozzetti F. et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. J Parenter Enteral Nutr 2000; 24: 7-14
• 404 Burden S. et al. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. Cochrane Database Syst Rev 2012; 11: CD008879
• 405 Bozzetti F. et al. Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin Nutr 2002; 21: 281-288
• 406 Scolapio JS. et al. Survival of home parenteral nutrition-treated patients: 20 years of experience at the Mayo Clinic. Mayo Clin Proc 1999; 74: 217-222
• 407 Nayel H, el-Ghoneimy E, el-Haddad S. Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation. Nutrition 1992; 8: 13-18
• 408 Fietkau R. et al. A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial. Cancer 2013; 119: 3343-3353
• 409 Tyldesley S. et al. The use of radiologically placed gastrostomy tubes in head and neck cancer patients receiving radiotherapy. Int J Radiat Oncol Biol Phys 1996; 36: 1205-1209
• 410 Huang EY. et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 2000; 46: 535-539
• 411 Cerchietti LC. et al. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L- glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1330-1337
• 412 Kozelsky TF. et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 2003; 21: 1669-1674
• 413 Rotovnik Kozjek N. et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. Clin Nutr 2011; 30: 567-570
• 414 Vidal-Casariego A. et al. Effects of oral glutamine during abdominal radiotherapy on chronic radiation enteritis: a randomized controlled trial. Nutrition 2015; 31: 200-204
• 415 Kucuktulu E. et al. The protective effects of glutamine on radiation-induced diarrhea. Support Care Cancer 2013; 21: 1071-1075
• 416 Salminen E. et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988; 39: 435-437
• 417 Urbancsek H. et al. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 2001; 13: 391-396
• 418 Delia P. et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 2007; 13: 912-915
• 419 Giralt J. et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation- induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008; 71: 1213-1219
• 420 Ligthart-Melis GC. et al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer. Dis Esophagus 2013; 26: 587-593
• 421 Cascinu S. et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-3483
• 422 Wang WS. et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007; 12: 312-319
• 423 Sanchez-Lara K. et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr 2014; 33: 1017-1023
• 424 Ravasco P. et al. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005; 27: 659-668
• 425 Ravasco P. et al. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005; 23: 1431-1438
• 426 Ravasco P, Monteiro-Grillo I, Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr 2012; 96: 1346-1353
• 427 Lawlor PG. et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000; 160: 786-794
• 428 Bruera E. et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol 2005; 23: 2366-2371
• 429 Raijmakers NJ. et al. Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Ann Oncol 2011; 22: 1478-1486
• 430 Bruera E. et al. Parenteral hydration in patients with advanced cancer: a multicenter, double- blind, placebo-controlled randomized trial. J Clin Oncol 2013; 31: 111-118
• 431 Nakajima N, Hata Y, Kusumuto K. A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies. J Palliat Med 2013; 16: 185-189
• 432 2013. I.W.G.T. The Charter Scaligero on Gastric Cancer: Follow-Up After Gastrectomy for Cancer. 10th International Gastric Cancer Congress (IGCC). 2013
• 433 D’Ugo D. et al. Follow-up: the evidence. Dig Surg 2013; 30: 159-168
• 434 Faller H. et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 2013; 31: 782-793
• 435 Fitzgerald RC. et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47: 436-444
• 436 Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol 2011; 18: e202-e209
• 437 Lerut T. Clinical Practice Guidelines Upper Gastrointestinal Cancer – update. KCE 2012
• 438 (IKNL), N.I.f.o.u.p.F.u.P.I.K.N. Gastric cancer. Nation-wide guideline. 2012
• 439 Goddard AF. et al. The management of gastric polyps. Gut 2010; 59: 1270-1276
• 440 Dinis-Ribeiro M. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94
• 441 (NICE), N.I.f.H.a.C.E. Capecitabine for the treatment of advanced gastric cancer. 2010
• 442 (NICE), N.I.f.H.a.C.E. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. 2010
• 443 Knight G, Earle CC, Cosby R. et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer. Program in Evidence-based Care Evidence-based Series 2011
• 444 (NICE), N.I.f.H.a.C.E. Ramucirumab for treating advanced gastric cancer or gastro- oesophageal junction adenocarcinoma previously treated with chemotherapy. 2016
• 445 Daroui P. et al. ACR Appropriateness Criteria(R) Resectable Stomach Cancer. Oncology (Williston Park) 2015; 29: 595-602, C3
• 446 Busweiler LA. et al. Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. Br J Surg 2016; 103: 1855-1863
• 447 Busweiler LA. et al. Textbook outcome as a composite measure in oesophagogastric cancer surgery. Br J Surg 2017; 104: 742-750
• 448 Higashi T. et al. Quality of gastric cancer care in designated cancer care hospitals in Japan. Int J Qual Health Care 2013; 25: 418-428
• 449 Iwamoto M, Nakamura F, Higashi T. Monitoring and evaluating the quality of cancer care in Japan using administrative claims data. Cancer Sci 2016; 107: 68-75
• 450 Healthcare Improvement, S., Upper GI Cancer. Clinical Quality Performance Indicators. v. 3.0. 2017.
• 451 Information Services, D. and S. National Health Services. Upper GI Cancer Quality Performance Indicators. Patients diagnosed during 2013. 2015
• 452 Information Services, D. and S. National Health Services. Upper GI Cancer Quality Performance Indicators. Patients diagnosed during January 2013 to December 2015. 2017
• 453 Belgian Health Care Knowledge, C. Quality indicators for the management of upper gastrointestinal cancer. Brussels: KCE; 2013